<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20260622069921N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2026-09-24</date_registration>
      <primary_sponsor>CMH Hyderabad</primary_sponsor>
      <public_title>Changes in Serum Lipid Profile After Levothyroxine Treatment in Adults With Subclinical Hypothyroidism</public_title>
      <acronym>LIPOTHY</acronym>
      <scientific_title>Effect of Levothyroxine Replacement on Serum Lipid Profile in Adults With Subclinical Hypothyroidism: A Prospective Interventional Study</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2026-10-05</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>112</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/93471</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: N/A, Blinding: Not blinded, Placebo: Not used, Assignment: Single, Purpose: Treatment, Other design features: Prospective single-arm interventional before-and-after study. Participants will be assessed at baseline before initiation of levothyroxine therapy and followed prospectively for 12 weeks, with predefined clinical and laboratory assessments at specified follow-up visits.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Subclinical hypothyroidism is a biochemical condition characterized by an elevated serum thyroid-stimulating hormone concentration with free thyroxine concentration within the reference range. It may be associated with metabolic abnormalities, including alterations in serum lipid concentrations. This study will prospectively evaluate changes in lipid parameters following levothyroxine replacement therapy..</hc_freetext>
      <i_freetext>Levothyroxine sodium will be administered orally at an initial dose of 1.6 μg/kg/day according to the predefined study protocol. The medication will be taken once daily in the morning on an empty stomach with water. Dose adjustments, if required, will be made according to predefined TSH targets and documented during follow-up..</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is Limitations in participant consent, data sharing policy of institute and
confidentiality of study participants.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr. Asad Mahmood</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>CMH Road, Saddar, Cantonment, CMH Hyderabad</address>
        <city>Hyderabad</city>
        <country1>Pakistan</country1>
        <zip>71110</zip>
        <telephone>+92 316 4757170</telephone>
        <email>asad1620@gmail.com</email>
        <affiliation>CMH Hyderabad</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dania Mudassar</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>CMH Road, Saddar, Cantonment</address>
        <city>Hyderabad</city>
        <country1>Pakistan</country1>
        <zip>71110</zip>
        <telephone>+92 341 5072055</telephone>
        <email>dania.mudassar@outlook.com</email>
        <affiliation>CMH Hyderabad</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Pakistan</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Adult aged 18 - 65 years.
Biochemically confirmed subclinical hypothyroidism, defined as elevated serum TSH with free T4 within the laboratory reference range.
Patients who are willing to initiate levothyroxine therapy according to the study protocol.
Patients willing to attend the scheduled follow-up visits for 12 weeks.</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Previously diagnosed overt hypothyroidism or hyperthyroidism.
Previous or current thyroid hormone replacement therapy.
Pregnancy or lactation.
Patients who decline or withdraw informed consent.
Patients unable or unwilling to comply with the treatment and follow-up</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>E03.9</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Hypothyroidism, unspecified</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Levothyroxine sodium will be administered orally at an initial dose of 1.6 μg/kg/day according to the predefined study protocol. The medication will be taken once daily in the morning on an empty stomach with water. Dose adjustments, if required, will be made according to predefined TSH targets and documented during follow-up.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Lipid Profile. Timepoint: Change in serum lipid levels at baseline (before initiation of levothyroxine therapy) and 12 weeks after initiation of therapy. Method of measurement: Fasting venous blood samples will be collected at baseline and at 12 weeks. Serum Lipid levels will be measured using the institution’s standard laboratory method.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Change in serum TSH concentration from baseline to 12 weeks. Timepoint: Baseline and 12 weeks after initiation of levothyroxine therapy. Method of measurement: Fasting venous blood samples will be collected at baseline and at 12 weeks. Serum TSH levels will be measured using the institution’s standard laboratory method.</sec_outcome>
      <sec_outcome>Time required to achieve biochemical euthyroidism, defined according to the predefined serum TSH target in the study protocol. Timepoint: Baseline and 12 weeks after initiation of levothyroxine therapy. Method of measurement: Fasting venous blood samples will be collected at baseline and at 12 weeks. Serum TSH levels will be measured using the institution’s standard laboratory method.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>CMH Hyderabad</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2026-01-01</approval_date>
        <contact_name>The Ethical Committee/Institutional Review Board of CMH Hyderabad</contact_name>
        <contact_address>CMH road, Saddar, Cantonment, CMH Hyderabad. Hyderabad Sindh Pakistan</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
